OPANA
Total Payments
$1.9M
Transactions
417
Doctors
21
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $18,709 | 13 | 1 |
| 2023 | $110,331 | 29 | 0 |
| 2022 | $25,139 | 17 | 4 |
| 2021 | $145,446 | 36 | 4 |
| 2020 | $156,556 | 48 | 1 |
| 2019 | $377,734 | 40 | 6 |
| 2018 | $228,247 | 26 | 3 |
| 2017 | $801,465 | 208 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 224 | 64.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $549,081 | 13 | 29.5% |
| Consulting Fee | $89,685 | 18 | 4.8% |
| Travel and Lodging | $17,677 | 53 | 0.9% |
| Food and Beverage | $3,261 | 109 | 0.2% |
Payments by Type
Research
$1.2M
224 transactions
General
$659,704
193 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN-LABEL SINGLE-DOSE AND RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF OXYMORPHONE HYDROCHLORIDE HCL FOR ACUTE MODERATE TO SEVERE POSTOPERATIVE PAIN IN PEDIATRIC SUBJECTS | Endo Pharmaceuticals Inc. | $309,858 | 3 |
| An Open-Label Single-Dose And Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oxymorphone Hydrochloride HCl For Acute Moderate To Severe Postoperative Pain In Pediatric Subjects | Endo Pharmaceuticals Inc. | $271,340 | 3 |
| Not Specific to one study | Endo Pharmaceuticals Inc. | $144,705 | 1 |
| A Randomized Double-Blind, Placebo-Controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-Dose Long-Term Opioid Analgesic Therapy for Chronic Pain | Endo Pharmaceuticals Inc. | $99,834 | 0 |
| Not Specific To One Study | Endo Pharmaceuticals Inc. | $98,725 | 1 |
| AN OPEN-LABEL SINGLE-DOSE AND RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF OXYMORPHONE HCL FOR ACUTE MODERATE TO SEVER POSTOPERATIVE PAIN IN PEDIATRIC SUBJECTS | Endo Pharmaceuticals Inc. | $83,932 | 3 |
| ER/LA Opioid PMR - Observational Study 1B | Endo Pharmaceuticals Inc. | $47,447 | 0 |
| 1B: Study #3033-2; Incidence and Predictors of Opioid Overdose and Death among ER/LA Opioid Analgesics Users as Measured by Diagnoses and Death Records A Retrospective Database Study | Endo Pharmaceuticals Inc. | $30,456 | 0 |
| A MULTICENTER STUDY OF THE SAFETY, TOLERABILITY, EFFECTIVENESS AND PHARMACOKINETICS OF OXYMORPHONE HCL EXTENDED RELEASE TABLETS IN PEDIATRIC SUBJECTS REQUIRING AN AROUND THE CLOCK ATC OPIOID FOR AN EXTENDED PERIOD OF TIME | Endo Pharmaceuticals Inc. | $25,876 | 0 |
| ER/LA Opiod PMR 3033-11 HST F2F | Endo Pharmaceuticals Inc. | $18,338 | 1 |
| PMR 3033-11: Study #2065-5; A Randomized Double-Blind, Placebo-Controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-Dose Long-Term Opioid Analgesic Therapy for Chronic Pain | Endo Pharmaceuticals Inc. | $14,966 | 1 |
| AN OPEN-LABEL SINGLE-DOSE AND RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF OXYMORPHONE HYDROCHLORIDE (HCL) FOR ACUTE MODERATE TO SEVERE POSTOPERATIVE PAIN IN PEDIATRIC SUBJECTS | Endo Pharmaceuticals Inc. | $14,493 | 0 |
| A MULTICENTER STUDY OF THE SAFETY, TOLERABILITY, EFFECTIVENESS AND PHARMACOKINETICS OF OXYMORPHONE HCL EXTENDED RELEASE TABLETS IN PEDIATRIC SUBJECTS REQUIRING AN AROUND THE CLOCK (ATC) OPIOID FOR AN EXTENDED PERIOD OF TIME | Endo Pharmaceuticals Inc. | $11,625 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF STRUCTURED OPIOID DISCONTINUATION VERSUS CONTINUED OPIOID THERAPY IN SUBOPTIMAL AND OPTIMAL RESPONDERS TO HIGH-DOSE LONG-TERM OPIOID ANALGESIC THERAPY FOR CHRONIC PAIN | Endo USA, Inc. | $10,200 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF STRUCTURED OPIOID DISCONTINUATION VERSUS CONTINUED OPIOID THERAPY IN SUBOPTIMAL AND OPTIMAL RESPONDERS TO HIGH-DOSE LONG-TERM OPIOID ANALGESIC THERAPY FOR CHRONIC PAIN | Endo Pharmaceuticals Inc. | $8,753 | 1 |
| STUDY TO VALIDATE CODED MEDICAL TERMINOLOGIES USED TO IDENTIFY OPIOID-RELATED OVERDOSE IN THE POSTMARKETING DATABASES EMPLOYED IN PMR STUDY 1B | Endo Pharmaceuticals Inc. | $4,914 | 1 |
| A Randomized Double Blind Placebo-Controlled Clinical Trial of Structured Opioid Discontinuation Verses Continued Opioid Therapy in Suboptimal and Optimal Responders to High-Dose Long Term Opioid Analgesic therapy for Chronic Pain as Measured by Quantitative Sensory Testing 3033-11 QST and 2065-5 QST | Endo Pharmaceuticals Inc. | $1,753 | 0 |
| A Randomized Double Blind Placebo-Controlled Clinical Trial of Structured Opioid Discontinuation Verses Continued Opioid Therapy in Suboptimal and Optimal Responders to High-Dose Long Term Opioid Analgesic therapy for Chronic Pain Protocol #2065-5 | Endo Pharmaceuticals Inc. | $1,469 | 0 |
| AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, ASCENDING DOSE BY AGE, SINGLE- AND MULTIPLE-DOSE EVALUATION OF THE EFFECTIVENESS, SAFETY, AND TOLERABILITY OF ORAL LIQUID OXYMORPHONE HCL IMMEDIATE-RELEASE ORAL LIQUID FOR ACUTE POSTOPERATIVE PAIN IN PEDIATRIC SUBJECTS | Endo Pharmaceuticals Inc. | $1,250 | 0 |
| A Randomized Double Blind Placebo-Controlled Clinical Trial of Structured Opioid Discontinuation Verses Continued Opioid Therapy in Suboptimal and Optimal Responders to High-Dose Long Term Opioid Analgesic therapy for Chronic Pain Protocol #3033-11 and 2065-5 | Endo Pharmaceuticals Inc. | $1,245 | 0 |
Top Doctors Receiving Payments for OPANA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winter Park, CO | $1.5M | 159 |
| , MD | General Practice | Chadds Ford, PA | $243,430 | 36 |
| Gavril Pasternak | — | New York, NY | $27,129 | 32 |
| , MD | Medical Toxicology | Aurora, CO | $14,232 | 21 |
| , MD | Addiction Medicine | Cincinnati, OH | $13,219 | 15 |
| , MD | Pediatrics | Hartford, CT | $13,070 | 7 |
| , M.D | Interventional Pain Medicine | Baltimore, MD | $11,550 | 5 |
| , MD | Neonatal-Perinatal Medicine | Washington, DC | $11,190 | 8 |
| , MD | General Practice | Torrance, CA | $8,182 | 10 |
| , MD | Anesthesiology | Stanford, CA | $6,452 | 5 |
| , M.D | Pain Medicine | Cleveland, OH | $6,421 | 10 |
| , DO | Pain Medicine | New Orleans, LA | $6,403 | 9 |
| , MD | Neurology | Rochester, NY | $6,391 | 7 |
| , MD | Neurology | Albany, NY | $6,174 | 10 |
| , MD | Addiction Medicine | Houston, TX | $6,141 | 9 |
| , M.D | Rheumatology | Houston, TX | $5,873 | 10 |
| , M.D | Public Health & General Preventive Medicine | Reston, VA | $5,635 | 9 |
| , MD | Internal Medicine | Philadelphia, PA | $4,914 | 13 |
| Richard Rauck | — | Winston Salem, NC | $2,160 | 2 |
| , MD | Pain Medicine | Salt Lake City, UT | $1,634 | 11 |
| , M.D | Family Medicine | Apple Valley, MN | $1,298 | 28 |
| , MD | Internal Medicine | Haverford, PA | $800.00 | 1 |
Ad
Manufacturing Companies
- Endo Pharmaceuticals Inc. $1.9M
- Endo USA, Inc. $11,143
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 21
- Transactions 417
About OPANA
OPANA is a drug associated with $1.9M in payments to 21 healthcare providers, recorded across 417 transactions in the CMS Open Payments database. The primary manufacturer is Endo Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $18,709 was paid across 13 transactions to 1 doctors.
The most common payment nature for OPANA is "Unspecified" ($1.2M, 64.6% of total).
OPANA is associated with 20 research studies, including "AN OPEN-LABEL SINGLE-DOSE AND RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF OXYMORPHONE HYDROCHLORIDE HCL FOR ACUTE MODERATE TO SEVERE POSTOPERATIVE PAIN IN PEDIATRIC SUBJECTS" ($309,858).